0,25 CFU -CREDIT FOR ADE

2018 ESC Guidelines for the diagnosis and management of syncope 

2018 ESC/ESH Guidelines for the management of arterial hypertension 

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

Cirrhosis is the irreversible fibrosis of the liver, the end stage

 of a final shared pathway in chronic damage to a major vital organ. It is

the 8th leading cause of death in the United States and the 13th leading

cause of death globally, with worldwide mortality having increased by 45.6% from

1990 to 2013.1  The pathophysiological features of cirrhosis involve progressive

liver injury and fibrosis resulting in portal hypertension and decompensation, including

ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, variceal

hemorrhage, the hepatorenal syndrome, and hepatocellular carcinoma. This article

reviews the practical treatment of patients with cirrhosis, with a focus on recent

developments. Our recommendations are based on results from clinical trials,

when available, and on current clinical practice when controlled trials have not

been conducted.

 GUIDE TO THE MEDICAL INTERVIEW – COMMUNICATION PROCESS

The aim of all the ESC Guidelines is to help health professionals to make decisions in their everyday life based on the best available evidence.

We will soon be celebrating the 30th anniversary of clinical trials that for the first time incontrovertibly demonstrated that the

miserable outcome of patients with heart failure (HF) can be markedly improved. Since then, in the area of HF management we have

witnessed and celebrated numerous highs, which have definitely outnumbered several lows, all of which have allowed us to unravel

the pathophysiology of this clinical syndrome, but more importantly has led to better care of our patients.3 In the year 2016, no one

would any longer dispute that, by applying all evidence-based discoveries,  HF is now becoming a preventable and treatable disease.

The aim of this document is to provide practical, evidence-based guidelines for the diagnosis and treatment of HF.

ACCADEMIA MEDICA DI ROMA

Giovedì 15 novembre 2018, h.16

Auditorium Prima Clinica Medica

Policlinico Umberto I, viale del Policlinico 155, Roma

16.00 Saluti del Presidente dell’Accademia Medica di Roma

16.10 Prolusione Magnifico Rettore Eugenio Gaudio

16.40 Presentazione Calendario Conferenze Anno Accademico 2018/2019

e Conferimento della nomina di Presidente Onorario

al Prof. Mario Stefanini

17.00 Conferenza del Prof. Giuseppe Remuzzi,

Direttore Istituto di Ricerche Farmacologiche Mario Negri IRCCS,

Professore di nefrologia, Università di Milano:

"Medicina del trapianto: da dove siamo partiti e

dove vorremmo (forse) arrivare"

chronic heart failure and gender differences